Aydin Huseynov
Stock Analyst at Ladenburg Thalmann & Co.
(0.08)
# 4,675
Out of 4,712 analysts
118
Total ratings
33.3%
Success rate
-18.1%
Average return
Main Sectors:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiated Coverage: Buy | $4 | $2.43 | +64.61% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiated Coverage: Buy | $40 | $10.96 | +264.96% | 1 | Jan 5, 2026 | |
| URGN UroGen Pharma | Reiterated: Buy | $31 → $55 | $43.82 | +25.53% | 2 | Nov 7, 2025 | |
| IMUX Immunic | Initiated Coverage: Buy | $30 | $12.74 | +135.48% | 1 | Oct 16, 2025 | |
| KALA KALA BIO | Initiated Coverage: Buy | $600 | $0.5379 | n/a | 1 | Jul 11, 2025 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $39 → $48 | $9.06 | n/a | 4 | Mar 20, 2025 | |
| ARDX Ardelyx | Maintained: Buy | $11 | $3.77 | n/a | 1 | Mar 7, 2025 | |
| BDRX Biodexa Pharmaceuticals | Maintained: Buy | $8 → $18 | $0.8308 | n/a | 2 | Jan 2, 2025 | |
| CLRB Cellectar Biosciences | Maintained: Buy | $390 | $2.41 | n/a | 1 | Dec 5, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintained: Buy | $21 → $24 | $13.93 | n/a | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $7 | $2.21 | n/a | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 → $19 | $1.28 | n/a | 2 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 | $2.10 | n/a | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.34 | n/a | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $1.01 | n/a | 3 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $1.35 | n/a | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $3.09 | n/a | 2 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $6 | $13.96 | n/a | 4 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 → $19 | $0.8625 | n/a | 4 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $59.09 | n/a | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $10 | $0.9872 | n/a | 3 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $23.99 | n/a | 2 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $6.13 | n/a | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $10 | $4.52 | n/a | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 → $240 | $2.20 | n/a | 3 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.15 | n/a | 3 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $1.70 | n/a | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0004 | n/a | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $8.42 | n/a | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.25 | n/a | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $1.30 | n/a | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $810.31 | n/a | 11 | Nov 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $26 → $20 | $75.44 | n/a | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $56.71 | n/a | 5 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $89 | $124.40 | n/a | 5 | Sep 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $3.40 | n/a | 5 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $2.63 | n/a | 2 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $2.16 | n/a | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 → $15 | $1.42 | n/a | 7 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $155.13 | n/a | 1 | Sep 30, 2020 |
Inhibikase Therapeutics
Mar 4, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $2.43
Upside: +64.61%
Akari Therapeutics,
Jan 5, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $10.96
Upside: +264.96%
UroGen Pharma
Nov 7, 2025
Reiterated: Buy
Price Target: $31 → $55
Current: $43.82
Upside: +25.53%
Immunic
Oct 16, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $12.74
Upside: +135.48%
KALA BIO
Jul 11, 2025
Initiated Coverage: Buy
Price Target: $600
Current: $0.5379
Upside: n/a
Capricor Therapeutics
Mar 20, 2025
Reiterated: Buy
Price Target: $39 → $48
Current: $9.06
Upside: n/a
Ardelyx
Mar 7, 2025
Maintained: Buy
Price Target: $11
Current: $3.77
Upside: n/a
Biodexa Pharmaceuticals
Jan 2, 2025
Maintained: Buy
Price Target: $8 → $18
Current: $0.8308
Upside: n/a
Cellectar Biosciences
Dec 5, 2024
Maintained: Buy
Price Target: $390
Current: $2.41
Upside: n/a
Corvus Pharmaceuticals
Nov 13, 2024
Maintained: Buy
Price Target: $21 → $24
Current: $13.93
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $5 → $7
Current: $2.21
Upside: n/a
Oct 21, 2024
Maintained: Buy
Price Target: $11 → $19
Current: $1.28
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $16
Current: $2.10
Upside: n/a
Aug 14, 2024
Reiterated: Buy
Price Target: $7
Current: $1.34
Upside: n/a
Jul 30, 2024
Maintained: Buy
Price Target: $6 → $5
Current: $1.01
Upside: n/a
Jun 27, 2024
Initiated Coverage: Buy
Price Target: $10
Current: $1.35
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: n/a
Current: $3.09
Upside: n/a
May 16, 2024
Maintained: Buy
Price Target: $8 → $6
Current: $13.96
Upside: n/a
Apr 18, 2024
Maintained: Buy
Price Target: $9 → $19
Current: $0.8625
Upside: n/a
Mar 14, 2024
Downgraded: Hold
Price Target: n/a
Current: $59.09
Upside: n/a
Nov 10, 2023
Reiterated: Buy
Price Target: $14 → $10
Current: $0.9872
Upside: n/a
Nov 9, 2023
Reiterated: Buy
Price Target: $21
Current: $23.99
Upside: n/a
Oct 10, 2023
Initiated Coverage: Buy
Price Target: $10
Current: $6.13
Upside: n/a
Jun 5, 2023
Maintained: Buy
Price Target: $20 → $10
Current: $4.52
Upside: n/a
May 16, 2023
Maintained: Buy
Price Target: $25 → $240
Current: $2.20
Upside: n/a
Mar 10, 2023
Downgraded: Hold
Price Target: n/a
Current: $7.15
Upside: n/a
Dec 7, 2022
Initiated Coverage: Buy
Price Target: $6
Current: $1.70
Upside: n/a
Nov 15, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.0004
Upside: n/a
Nov 4, 2022
Downgraded: Hold
Price Target: n/a
Current: $8.42
Upside: n/a
Aug 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $1.25
Upside: n/a
May 2, 2022
Initiated Coverage: Buy
Price Target: $37
Current: $1.30
Upside: n/a
Nov 9, 2021
Maintained: Hold
Price Target: n/a
Current: $810.31
Upside: n/a
Nov 8, 2021
Upgraded: Buy
Price Target: $26 → $20
Current: $75.44
Upside: n/a
Oct 21, 2021
Maintained: Hold
Price Target: n/a
Current: $56.71
Upside: n/a
Sep 23, 2021
Maintained: Buy
Price Target: $89
Current: $124.40
Upside: n/a
Sep 20, 2021
Maintained: Buy
Price Target: $9
Current: $3.40
Upside: n/a
Aug 6, 2021
Rated: Buy
Price Target: $5
Current: $2.63
Upside: n/a
Jun 21, 2021
Reiterated: Buy
Price Target: $15
Current: $2.16
Upside: n/a
Jan 8, 2021
Maintained: Buy
Price Target: $25 → $15
Current: $1.42
Upside: n/a
Sep 30, 2020
Initiated Coverage: Hold
Price Target: n/a
Current: $155.13
Upside: n/a